Abstract: The present invention relates to transgenic wheat plants. In particular, the present invention relates to a stress tolerant wheat plant, wherein said wheat plant has been transformed with a nucleic acid molecule, which codes for ornithine amino transferase (OAT).
Type:
Application
Filed:
July 29, 2005
Publication date:
February 14, 2008
Applicant:
Grain Biotech Australia Pty Ltd.
Inventors:
Scott McNeil, Douglas Chamberlain, Robert Bower
Abstract: The existence and the extent of periodontal disease can be diagnosed by measuring plasminogen activator inhibitor 2 (PAI-2) and/or tissue plasminogen activator (t-PA) levels in gingival crevicular fluid (GCF). Levels of PAI-2 and t-PA in GCF rise sharply in the context of periodontal disease, and they also correlate with the severity of disease at different sites in the same patient.
Type:
Grant
Filed:
January 26, 1999
Date of Patent:
June 18, 2002
Assignee:
Biotech Australia Pty Ltd
Inventors:
Yin Xiao, Clive L. Bunn, Peter M. Bartold
Abstract: The healing of chronic wounds, such as leg ulcers, is accelerated via topical administration of a serine protease inhibitor, such as PAI-2. Wound healing also is promoted using combinations of protease inhibitors, such as PAI-2 with other serine protease inhibitors and/or with protease inhibitors such inhibitors of metalloproteinases, acid proteases, and thiol proteases, respectively.
Type:
Grant
Filed:
November 13, 1998
Date of Patent:
February 5, 2002
Assignee:
Biotech Australia Pty., Ltd.
Inventors:
Clive Leighton Bunn, John Lewis Andrews, Phillip John Sharp
Abstract: There are disclosed complexes and compositions for oral delivery of a substance or substances to the circulation or lymphatic drainage system of a host. The complexes of the invention comprise a microparticle coupled to at least one carrier, the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host, and the microparticle entrapping or encapsulating, or being capable of entrapping or encapsulating, the substance(s). Examples of suitable carriers are mucosal binding proteins, bacterial adhesins, viral adhesins, toxin binding subunits, lectins, Vitamin B.sub.12 and analogues or derivatives of Vitamin B.sub.12 possessing binding activity to Castle's intrinsic factor.
Type:
Grant
Filed:
November 30, 1992
Date of Patent:
December 12, 2000
Assignee:
Biotech Australia Pty LTD
Inventors:
Gregory John Russell-Jones, Steven William Westwood
Abstract: The present invention provides novel LHRH antagonists and complexes between these antagonists and VB12. The present invention is particularly useful for the oral administration of LHRH antagonists. The antagonists of the invention are selected from the group consisting of ANTIDE-1, ANTIDE-2 and ANTIDE-3.
Abstract: T-cell epitopes of or derived from the TraT protein of E. coli have been identified and used in the preparation of complexes with immunogens to enhance or provide immune responses to the immunogens. The complexes can be prepared directly, by chemical linkage, or as fusion proteins. In the latter context, polynucleotides encode a fusion protein which a transformed host can express. The fusion proteins may be expressed intracellularly or exported to and expressed on the surface of the transformant host.
Type:
Grant
Filed:
March 16, 1993
Date of Patent:
March 19, 1996
Assignee:
Biotech Australia Pty. Ltd.
Inventors:
Gregory J. Russell-Jones, Andrew F. Geczy